When you focus on what matters, it matters

Pioneering discoveries from the bench to the bedside

Behind every advancement is a team focused on the same goal—to deliver the essential next-generation CAR T-cell therapies. Our mission is to enhance the treatment experience across a range of hematologic and oncologic conditions. Because your focus is our focus: providing life-changing treatments for patients.

Delivering on the details that drive innovation

Autolus is focused on engineering greatness—in both efficacy and efficiency.

Widely respected in Europe for its trailblazing work in CAR T science, Autolus is now working to transform treatment for those with difficult-to-treat cancers, including acute lymphoblastic leukemia (ALL), in the United States. We apply our broad array of T-cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T-cell therapies. These are designed to better recognize cancer cells, break down their defense mechanisms, and eradicate them. View our abstracts and publications to learn more about our ongoing discoveries.

Developing MOAs designed to deliver

Autolus recognizes that increasing activity and reducing toxicity are crucial to CAR T performance.

While CAR T-cell therapy has been transformative in cancer care, it can also trigger severe immunotoxicities. At Autolus, we are focused on advancing the class with a novel CAR construct featuring fast off-rate kinetics similar to the behavior of naturally occurring T cells, designed to enhance in vivo expansion, extend CAR T-cell persistence, and provide greater tolerability for patients with certain types of leukemia. Learn more about fast off-rate binding CARs included in our clinical trials.

Additionally, Autolus is addressing immunotoxicity with tailored dosing that’s designed to minimize toxicities by giving physicians more control over their patients’ treatment.

Delivering rapid, consistent, and reliable manufacturing

Every CAR T-cell treatment dose at Autolus is manufactured at Nucleus, a 70,000 square foot, fully enclosed, semi-automated manufacturing facility. With the ability to rapidly scale up with demand, our state-of-the-art manufacturing process engineers your patients’ T cells with speed and precision.

Delivering collaborations to power transformations

A decade after evolving from our academic origins, Autolus maintains the pioneering spirit, passion, and boundless curiosity that charged the university lab environment. Now, by sharing findings and proprietary technologies with other industry leaders, Autolus is encouraging immunotherapy innovation on multiple fronts.

Other biotechnology companies are pursuing collaborations with Autolus for use of its state-of-the-art manufacturing facility and clinical networks, and the option to license its cell programming technology and proprietary binders.

Delivering a pipeline to answer unmet needs—today and tomorrow

CAR T-cell therapy has shown tremendous promise for a few blood cancers, but patients with other rare forms of cancer have long been left out of the CAR T-cell revolution.

Adult patients with ALL, AML, CLL, T-cell lymphoma, and solid tumors have limited or no CAR T-cell treatment options. In response, Autolus supports several ongoing CAR T-cell clinical trials that promise new treatment options—and new hope—to these patients, by making sure patients enrolled in our clinical trials reflect real-world populations and needs.

But we aren’t doing it alone: Autolus embraces partnerships and shares discoveries with other biotech companies, because improving outcomes for people living with cancer is the collective goal.

Delivering an innovative treatment approach tailored to each patient

Every Autolus product is designed to optimize the treatment journey for patients. For those receiving or providing treatment with Autolus products, our patient support can help patients and caregivers access resources to help smooth the process, including travel, housing, and meal support.

For people who are either considering enrolling or are already enrolled in a CAR T-cell therapy clinical trial, Autolus provides a comprehensive guide to CAR T-cell therapy for patients and caregivers. This educational resource walks the reader through the treatment journey, and also serves as a helpful teaching aid for clinical staff managing CAR T clinical trials.

Delivering new insights for building strong relationships

There’s more to explore at Autolus. We invite you to learn more about our shared purpose, 2024 overview, and recent news.

Interested in learning more? We’d love to start a conversation—please reach out to us.